Safety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials

M. Mau-Sorensen, M. van Bussel, M. Kuipers, D. L. Nielsen, H. M. Verheul, P. Aftimos, M. J.A. de Jonge, B. van Triest, J. Falkenius, J. Debus, E. Troost, M. Samuels, B. Sarholz, V. Budach, S. Goel, G. Locatelli, P. F. Geertsen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)viii654
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - 1 Oct 2018

Cite this